— Know what they know.
Not Investment Advice

SVRA NASDAQ

Savara Inc.
1W: +2.1% 1M: -4.1% 3M: -8.0% YTD: -13.8% 1Y: +11.5% 3Y: +50.0% 5Y: +285.7%
$4.86
+0.34 (+7.52%)
 
Weekly Expected Move ±6.9%
$4 $4 $4 $5 $5
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 30 · $998.5M mcap · 103M float · 1.95% daily turnover · Short 58% of daily vol
Credit Risk of going bust: lower than 71% of companies Debt: 2.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.7%), Savara Inc. would be worth roughly what it owes.
Total debt $30.1M against a stock market value of $998.5M.
Distance to default 7.81 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $15.1M (short-term plus half of long-term), stock volatility 53.4%; Altman Z'' -7.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Supply Chain Overview

10 relationships
10
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-06-04
Earliest Filing
2026-03-13
Latest Filing
partner: 5 supplier: 4 investor: 1

Counterparties (Filed by SVRA)

10 relationships

Companies named in SVRA's SEC 8-K filings as business counterparties.

Counterparty Ticker Relationship Summary Filing Date SEC
ML7 Yardley Partners, LP — partner Savara Inc. entered into a lease agreement for office space with ML7 Yardley Partners, LP. 2026-03-13 View
RTW Investments, LP — investor Purchaser of assigned interests in MOLBREEVI for royalty payments upon FDA approval. 2025-10-29 View
Jefferies LLC JEF partner Served as underwriter representative in the common stock offering 2024-06-28 View
Piper Sandler & Co. PIPR partner Served as underwriter representative in the common stock offering 2024-06-28 View
Fujifilm Diosynth Biotechnologies UK Limited — supplier Provider of development and manufacturing services for molgramostim active pharmaceutical ingredient 2024-02-16 View
Fujifilm Diosynth Biotechnologies Texas, LLC — supplier Provider of development and manufacturing services for molgramostim active pharmaceutical ingredient 2024-02-16 View
Fujifilm Diosynth Biotechnologies U.S.A., Inc. — supplier Provider of development and manufacturing services for molgramostim active pharmaceutical ingredient 2024-02-16 View
Evercore Group L.L.C. EVR partner Sales agent for Savara Inc. common stock offering 2021-07-07 View
H.C. Wainwright & Co., LLC — partner Previous sales agent whose agreement was terminated 2021-07-07 View
Overlook at Rob Roy Owner, LLC — supplier Lease agreement for office space 2021-06-04 View
Recent 8-K Filings (20)
Filing Date Description Type SEC
2026-06-08 Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits View
2026-03-13 Entry into Material Definitive Agreement; Financial Statements and Exhibits Agreement View
2026-01-27 Entry into Material Definitive Agreement; Creation of Direct Financial Obligation Agreement View
2026-01-09 Regulation FD Disclosure; Financial Statements and Exhibits View
2025-10-30 Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits Agreement View
2025-10-29 Entry into Material Definitive Agreement; Regulation FD Disclosure; Other Events; Financial Statemen Agreement View
2025-09-02 Regulation FD Disclosure; Financial Statements and Exhibits View
2025-06-06 Submission of Matters to a Vote of Security Holders View
2025-05-27 Other Events; Financial Statements and Exhibits View
2025-03-31 Termination of Material Definitive Agreement View
2025-03-26 Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Creation of Agreement View
2025-01-23 Departure/Election of Directors; Appointment of Officers View
2025-01-13 Regulation FD Disclosure; Financial Statements and Exhibits View
2024-06-28 Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits Agreement View
2024-06-26 Regulation FD Disclosure; Other Events; Financial Statements and Exhibits View
2024-06-10 Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits View
2024-06-07 Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde View
2024-02-16 Entry into Material Definitive Agreement Agreement View
2024-01-25 Departure/Election of Directors; Appointment of Officers View
2024-01-05 Regulation FD Disclosure; Financial Statements and Exhibits View
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text. Covers 2021–2026. View on SEC EDGAR

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms